EXONDYS 51
PeakRNAeteplirsen
NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein, which was evaluated in Study 2 and Study 3…
Pharmacologic Class:
Antisense Oligonucleotide
Indications (1)
Loss of Exclusivity
LOE Date
Mar 14, 2034
97 months away
Patent Expiry
Mar 14, 2034